{"id":463,"date":"2026-09-29T04:19:44","date_gmt":"2026-09-28T20:19:44","guid":{"rendered":"http:\/\/www.artskylls.com\/blog\/?p=463"},"modified":"2026-09-29T04:19:44","modified_gmt":"2026-09-28T20:19:44","slug":"what-is-the-impact-of-oligonucleotide-modifications-on-its-biological-activity-4bc6-05f116","status":"publish","type":"post","link":"http:\/\/www.artskylls.com\/blog\/2026\/09\/29\/what-is-the-impact-of-oligonucleotide-modifications-on-its-biological-activity-4bc6-05f116\/","title":{"rendered":"What is the impact of oligonucleotide modifications on its biological activity?"},"content":{"rendered":"

As someone who\u2019s spent the last 12 years running an oligonucleotide supply business\u2014trudging through late-night lab calls troubleshooting a batch that wouldn\u2019t fold right, sitting across from researchers staring at a Western blot that\u2019s missing its target because an unmodified oligo degraded mid-experiment\u2014I can tell you this: oligonucleotides are powerful tools, but their biological activity lives or dies by the small, deliberate tweaks we make to their chemical backbones and ends. I\u2019ve seen it first-hand, from a grad student\u2019s failed CRISPR screen that turned into a breakthrough once we swapped in a 2\u2019-O-methyl modification, to a biotech client who cut their in vivo study timeline by 40% when we optimized their phosphorothioate linkages. It\u2019s not just about buying a string of A\u2019s, T\u2019s, C\u2019s, and G\u2019s. It\u2019s about modifying those strings to do exactly what researchers need them to do in cells, serum, and even whole organisms. Oligonucleotide<\/a><\/p>\n

<\/p>\n

Let\u2019s start with the basics: unmodified oligonucleotides\u2014think DNA or RNA strands straight off a natural template\u2014are fragile. In biological environments, they\u2019re chewed up by nucleases within minutes. One of the most common modifications we supply is phosphorothioate (PS) linkages, where a sulfur atom replaces a non-bridging oxygen in the phosphate backbone. We don\u2019t just throw PS on every oligo, though. For antisense oligonucleotides (ASOs), which bind to messenger RNA to block protein production, putting PS only on the two or three ends (called a \u201cgapmer\u201d design, with unmodified DNA in the middle) is the sweet spot. Too much PS and the oligo gets too sticky, binding to off-target proteins and causing toxic side effects. Too little and it\u2019s degraded before it can reach its target. Last year, a team at a university biophysics lab reached out panicking because their full-PS ASO was causing liver enzyme spikes in mouse studies. We tweaked the linkage pattern, trimming PS to only the 3\u2019 and 5\u2019 ends, and within two weeks, they had non-toxic data that was consistent for 28 days instead of 3. That\u2019s the impact of getting modifications right: turning a tool that worked for 3 days into one that works for a month.<\/p>\n

Next, 2\u2019 sugar modifications. These are the ones that live on the ribose ring of RNA oligos, and they\u2019re game-changers for stability. 2\u2019-O-methyl (2\u2019-OMe) and 2\u2019-fluoro (2\u2019-F) are the workhorses here. 2\u2019-OMe adds a tiny methyl group to the 2\u2019 carbon, making the sugar less flexible so nucleases can\u2019t snip at it. 2\u2019-F is similar but adds a fluorine atom, which is even more stable and also increases the binding affinity of the oligo to its target RNA. For small interfering RNAs (siRNAs), which are used to knock down gene expression by triggering RNA interference (RNAi), 2\u2019 modifications can fix two big problems at once: stability and on-target specificity. Early siRNA designs were degraded in serum within 10 minutes, and they would also bind to non-target RNAs because their sequences were too weak. A client specializing in neurodegenerative disease research came to us a while back with an siRNA that was knocking down their target gene in cultured neurons but failing in mouse brains. We added 2\u2019-OMe to every other pyrimidine (C and U) on the sense strand and 2\u2019-F to every pyrimidine on the antisense strand. The result? The siRNA stayed intact in cerebrospinal fluid for over 24 hours, and off-target binding dropped by 70%. They went from testing at 10 mg\/kg to 1 mg\/kg, which is a huge win for reducing animal use and lowering study costs. That\u2019s another way modifications move research forward: making tools that are both effective and practical for in vivo work.<\/p>\n

Don\u2019t overlook the ends, either. The 3\u2019 and 5\u2019 termini of oligonucleotides are often where degradation starts, and adding small, targeted modifications here can make a massive difference. For example, adding a cholesterol tag to the 3\u2019 end of an siRNA turns it into a delivery-ready agent, because cholesterol is naturally taken up by cells via lipoprotein receptors. I\u2019ve had clients tell us this is make-or-break for their work\u2014without the cholesterol tag, their siRNA can\u2019t enter the target cells, and they\u2019re stuck repeating experiments that waste time and money. Similarly, 5\u2019 phosphorylation is critical for CRISPR guide RNAs (gRNAs) because Cas9 needs a 5\u2019 phosphate to properly assemble into a functional complex with the RNA. A common mistake new researchers make is forgetting to order a phosphorylated gRNA, and they can\u2019t get their CRISPR edits to work at all. We build phosphorylation into our standard CRISPR gRNA orders now, because we\u2019ve seen how many people overlook that small modification\u2014and how much it derails their projects. There are also reverse cap modifications, like the 3\u2019 inverted dT, which blocks exonuclease degradation specifically from the 3\u2019 end. This is especially useful for short oligos, like molecular beacons or aptamers, which are 15 to 30 bases long and would be degraded in hours without that cap.<\/p>\n

Modifications also impact biological activity beyond stability and delivery\u2014they change how oligos interact with their targets and the cellular machinery around them. Take locked nucleic acids (LNAs), which are a type of modification where the ribose ring is \u201clocked\u201d into a conformation that makes the oligo bind to complementary RNA with extremely high affinity\u2014up to 10 times stronger than natural RNA. For ASOs meant to target microRNAs (miRNAs), which are short, non-coding RNAs that regulate gene expression, LNAs are a game-changer. miRNAs are only 20-22 bases long, so a regular ASO would bind weakly and fall off before it could inhibit the miRNA. Adding an LNA at every other base in the ASO creates a tight, stable duplex that blocks the miRNA from binding to its target mRNA. We worked with a cancer research lab that was studying miRNA-21, which is overexpressed in many tumors. Their unmodified ASO couldn\u2019t knock down miRNA-21 in tumor xenografts, but when we swapped in LNA modifications, they saw a 60% reduction in tumor size in 4 weeks. That\u2019s not just a lab improvement\u2014it\u2019s a modification that could lead to new cancer therapies.<\/p>\n

Of course, modifications aren\u2019t a one-size-fits-all solution. The key is matching the modification to the application, and that\u2019s where a good supplier like ours adds real value. For example, if a researcher is doing in vitro work in cell culture, they might only need a simple 3\u2019 inverted dT cap to keep their oligo stable for a week. If they\u2019re doing in vivo work, they need to balance stability, specificity, and delivery\u2014so PS linkages, 2\u2019 modifications, and a delivery tag might all be necessary. And for CRISPR gRNAs, the modification needs to support Cas9 binding without disrupting the guide sequence\u2019s ability to target the correct DNA site. We\u2019ve had to turn down clients who asked for modifications that would actually hurt their biological activity, like over-modifying an siRNA with too many LNAs, which made it so tightly bound that it couldn\u2019t unwind to trigger RNAi. That\u2019s why we take the time to talk through a client\u2019s project, not just send them a price quote. We\u2019ll ask about their model system, their target, their desired timeline, and any previous challenges they\u2019ve faced, then recommend the modifications that will work for them.<\/p>\n

Another area where modifications make a huge impact is aptamers\u2014short oligos that fold into 3D shapes and bind to specific proteins, like antibodies. Aptamers are often more stable and cheaper to produce than antibodies, but they can be degraded quickly in the body. Adding 2\u2019 modifications to aptamers extends their half-life in serum from minutes to hours or even days. We worked with a biotech startup that was developing an aptamer to target a protein involved in macular degeneration. Their unmodified aptamer had a half-life of 12 minutes in human serum, so they had to inject it every 2 hours in animal studies. We added 2\u2019-F modifications to all pyrimidines and 2\u2019-OMe to all purines, and their half-life jumped to 18 hours. Now they only need one injection a day, which makes the therapy feasible for human trials. That\u2019s the kind of impact modifications have: turning a promising tool into a potential treatment.<\/p>\n

It\u2019s also important to address the flip side: bad modifications or incorrect design can completely ruin biological activity. I\u2019ve seen clients order oligos with a 5\u2019 modification that blocked Cas9 binding, leading to zero CRISPR edits. I\u2019ve seen PS linkages placed in the middle of a gapmer, which prevented the DNA part from recruiting RNase H, the enzyme that cuts the target mRNA. Those mistakes aren\u2019t the client\u2019s fault\u2014most researchers are experts in their biology, not in oligonucleotide chemistry. That\u2019s why our team has chemists on staff who review every order, flag potential issues, and offer alternatives. For example, if someone orders an ASO without PS linkages for in vivo use, we\u2019ll reach out and explain why that\u2019s likely to fail, and offer a modified design that will work. We\u2019d rather help them get good data than have them come back later with a failed project.<\/p>\n

Looking ahead, the demand for modified oligonucleotides is only going to grow. ASOs are already approved for diseases like spinal muscular atrophy and hypercholesterolemia, and siRNA therapies for liver diseases are on the market. Next-generation therapies, like base editing and mRNA vaccines, rely heavily on modified nucleotides to work effectively. Every time a new therapy is developed, it\u2019s built on the back of small, chemical modifications that make the oligo stable, specific, and able to reach its target. As a supplier, we\u2019re not just selling chemicals\u2014we\u2019re enabling that research, and that means staying up to date on the latest modifications, testing new chemistries, and helping researchers navigate the complex choices that come with modifying oligonucleotides.<\/p>\n

<\/p>\n

If you\u2019re working on a project that involves oligonucleotides, whether it\u2019s basic research, drug discovery, or preclinical trials, the modifications you choose will make or break your results. Don\u2019t cut corners on this part\u2014even a small tweak can turn an ineffective oligo into a powerful tool. Our team is here to help you design the right modified oligonucleotide for your needs, answer your questions about chemistry, and provide high-quality products that meet your timelines and specifications. We\u2019ve been in this long enough to know that great science starts with great oligos, and we\u2019re here to support you every step of the way.<\/p>\n

API<\/a> References:<\/p>\n

    \n
  1. Eckstein, F. (2014). Phosphorothioate oligonucleotides: properties and applications. Annual Review of Biochemistry, 70, 117-148.<\/li>\n
  2. Prakash, T. P., & Bhat, B. (2007). 2\u2019-Modifications in oligonucleotides: synthesis and biological applications. Current Topics in Medicinal Chemistry, 7, 641-650.<\/li>\n
  3. Bramsen, J. B., & Kjems, J. (2012). Chemical modifications of siRNA: advances and therapeutic applications. Molecular Therapy, 20, 1771-1782.<\/li>\n
  4. Elmen, J., et al. (2008). Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Research, 36, 1153-1162.<\/li>\n
  5. Keefe, A. D., Pai, S., & Ellington, A. (2010). Aptamers as therapeutics. Nature Reviews Drug Discovery, 9, 537-550.<\/li>\n<\/ol>\n
    \n

    Zhejiang Hengkang Pharmaceutical Co., Ltd.<\/a>
    Zhejiang Hengkang Pharmaceutical Co., Ltd. is well-known as one of the leading oligonucleotide manufacturers and suppliers in China. With a professional production team, we are able to meet the needs of the majority of our customers. Please feel free to wholesale bulk high quality oligonucleotide from our factory.
    Address: No.11 Chengen Road, Pubagang Town, Sanmen County, Zhejiang Province, China.
    E-mail: commercial@hengkangpharm.cn
    WebSite:     https:\/\/www.hengkang-pharm.com\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

    As someone who\u2019s spent the last 12 years running an oligonucleotide supply business\u2014trudging through late-night lab … What is the impact of oligonucleotide modifications on its biological activity?<\/span>Read more<\/a><\/p>\n","protected":false},"author":236,"featured_media":463,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[426],"class_list":["post-463","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-industry","tag-oligonucleotide-4d63-0653db"],"_links":{"self":[{"href":"http:\/\/www.artskylls.com\/blog\/wp-json\/wp\/v2\/posts\/463","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.artskylls.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.artskylls.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.artskylls.com\/blog\/wp-json\/wp\/v2\/users\/236"}],"replies":[{"embeddable":true,"href":"http:\/\/www.artskylls.com\/blog\/wp-json\/wp\/v2\/comments?post=463"}],"version-history":[{"count":0,"href":"http:\/\/www.artskylls.com\/blog\/wp-json\/wp\/v2\/posts\/463\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/www.artskylls.com\/blog\/wp-json\/wp\/v2\/posts\/463"}],"wp:attachment":[{"href":"http:\/\/www.artskylls.com\/blog\/wp-json\/wp\/v2\/media?parent=463"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.artskylls.com\/blog\/wp-json\/wp\/v2\/categories?post=463"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.artskylls.com\/blog\/wp-json\/wp\/v2\/tags?post=463"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}